Literature DB >> 24970760

Podocalyxin-like 1 promotes invadopodia formation and metastasis through activation of Rac1/Cdc42/cortactin signaling in breast cancer cells.

Cheng-Wei Lin1, Min-Siou Sun2, Mei-Ying Liao3, Chu-Hung Chung3, Yi-Hsuan Chi3, Li-Tin Chiou3, John Yu4, Kuo-Lung Lou5, Han-Chung Wu6.   

Abstract

Metastatic disease is the leading cause of cancer mortality. Identifying biomarkers and regulatory mechanisms is important toward developing diagnostic and therapeutic tools against metastatic cancer. In this study, we demonstrated that podocalyxin-like 1 (PODXL) is overexpressed in breast tumor cells and increased in lymph node metastatic cancer. Mechanistically, we found that the expression of PODXL was associated with cell motility and invasiveness. Suppression of PODXL in MDA-MB-231 cells reduced lamellipodia formation and focal adhesion kinase (FAK) and paxillin phosphorylation. PODXL knockdown reduced the formation of invadopodia, such as inhibiting the colocalization of F-actin with cortactin and suppressing phosphorylation of cortactin and neural Wiskott-Aldrich syndrome protein. Conversely, overexpression of PODXL in MCF7 cells induced F-actin/cortactin colocalization and enhanced invadopodia formation and activation. Invadopodia activity and tumor invasion in PODXL-knockdown cells are similar to that in cortactin-knockdown cells. We further found that the DTHL motif in PODXL is crucial for regulating cortactin phosphorylation and Rac1/Cdc42 activation. Inhibition of Rac1/Cdc42 impeded PODXL-mediated cortactin activation and FAK and paxillin phosphorylation. Moreover, inhibition of PODXL in MDA-MB-231 cells significantly suppressed tumor colonization in the lungs and distant metastases, similar to those in cortactin-knockdown cells. These findings show that overexpression of PODXL enhanced invadopodia formation and tumor metastasis by inducing Rac1/Cdc42/cortactin signaling network.
© The Author 2014. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24970760     DOI: 10.1093/carcin/bgu139

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  28 in total

1.  MicroRNA-375 Suppresses Extracellular Matrix Degradation and Invadopodial Activity in Head and Neck Squamous Cell Carcinoma.

Authors:  Lizandra Jimenez; Ved P Sharma; John Condeelis; Thomas Harris; Thomas J Ow; Michael B Prystowsky; Geoffrey Childs; Jeffrey E Segall
Journal:  Arch Pathol Lab Med       Date:  2015-07-14       Impact factor: 5.534

2.  Role of EHD2 in migration and invasion of human breast cancer cells.

Authors:  Xiaojing Yang; Hanru Ren; Li Yao; Xueyu Chen; Aina He
Journal:  Tumour Biol       Date:  2015-01-05

3.  A RhoG-mediated signaling pathway that modulates invadopodia dynamics in breast cancer cells.

Authors:  Silvia M Goicoechea; Ashtyn Zinn; Sahezeel S Awadia; Kyle Snyder; Rafael Garcia-Mata
Journal:  J Cell Sci       Date:  2017-02-15       Impact factor: 5.285

4.  Podocalyxin Expressed in Antigen Presenting Cells Promotes Interaction With T Cells and Alters Centrosome Translocation to the Contact Site.

Authors:  Laura Amo; Javier Díez-García; Estíbaliz Tamayo-Orbegozo; Natalia Maruri; Susana Larrucea
Journal:  Front Immunol       Date:  2022-05-31       Impact factor: 8.786

5.  A Direct Podocalyxin-Dynamin-2 Interaction Regulates Cytoskeletal Dynamics to Promote Migration and Metastasis in Pancreatic Cancer Cells.

Authors:  Bin Sheng Wong; Daniel J Shea; Panagiotis Mistriotis; Soontorn Tuntithavornwat; Robert A Law; Jake M Bieber; Lei Zheng; Konstantinos Konstantopoulos
Journal:  Cancer Res       Date:  2019-04-11       Impact factor: 13.312

6.  Co-Expression of Ezrin-CLIC5-Podocalyxin Is Associated with Migration and Invasiveness in Hepatocellular Carcinoma.

Authors:  Teresita N J Flores-Téllez; Tania V Lopez; Verónica Rocío Vásquez Garzón; Saúl Villa-Treviño
Journal:  PLoS One       Date:  2015-07-02       Impact factor: 3.240

7.  Podocalyxin enhances breast tumor growth and metastasis and is a target for monoclonal antibody therapy.

Authors:  Kimberly A Snyder; Michael R Hughes; Bradley Hedberg; Jill Brandon; Diana Canals Hernaez; Peter Bergqvist; Frederic Cruz; Kelvin Po; Marcia L Graves; Michelle E Turvey; Julie S Nielsen; John A Wilkins; Shaun R McColl; John S Babcook; Calvin D Roskelley; Kelly M McNagny
Journal:  Breast Cancer Res       Date:  2015-03-27       Impact factor: 6.466

8.  Significant association and synergistic adverse prognostic effect of podocalyxin-like protein and epidermal growth factor receptor expression in colorectal cancer.

Authors:  Anna H Larsson; Sophie Lehn; Sakarias Wangefjord; Emelie Karnevi; Eugenia Kuteeva; Magnus Sundström; Björn Nodin; Mathias Uhlén; Jakob Eberhard; Helgi Birgisson; Karin Jirström
Journal:  J Transl Med       Date:  2016-05-10       Impact factor: 5.531

9.  Bmi1 essentially mediates podocalyxin-enhanced Cisplatin chemoresistance in oral tongue squamous cell carcinoma.

Authors:  Yueying Zhou; Leiyi Zhang; Hao Pan; Baisheng Wang; Fei Yan; Xiaodan Fang; Krishna Munnee; Zhangui Tang
Journal:  PLoS One       Date:  2015-04-27       Impact factor: 3.240

Review 10.  Involvement of platelet-tumor cell interaction in immune evasion. Potential role of podocalyxin-like protein 1.

Authors:  Laura Amo; Estíbaliz Tamayo-Orbegozo; Natalia Maruri; Cristina Eguizabal; Olatz Zenarruzabeitia; Marta Riñón; Arantza Arrieta; Silvia Santos; Jorge Monge; Miguel Angel Vesga; Francisco Borrego; Susana Larrucea
Journal:  Front Oncol       Date:  2014-09-11       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.